Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 2, 1999, Pages 179-186

  Dekkers, C P M ^a   Beker, J A ^b   Thjodleifsson, B ^c   Gabryelewicz, A ^d   Bell, N E ^e   Humphries, T J ^e   Hoang, P ^f   Van Laethem, J L ^f   Klein, C ^f   Krupp, P ^f   Raps, D ^f   Dettmer, A ^f   Burlefinger, R ^f   Crowe, J P ^f   Keeling, P W N ^f   Dekkers, C ^f   Beker, J ^f   Butruk, E ^f   Popiela, T ^f   Marlicz, K ^f   Berenguer, J ^f   Diaz Rubio, M ^f   Herrerias, J M ^f   Soderlind, A ^f   Tanghoj, H ^f   Wright, I ^f   Kerr, G D ^f   Swain, P ^f   Bennett, J R ^f   more..

^a Ignatius Hospital   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e EISAI CO LTD   (Japan)

^f Hammersmith International Centre ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; GASTRIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DUODENUM ULCER; ENDOSCOPY; FEMALE; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SWEATING; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DUODENAL ULCER; FEMALE; GASTRINS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 0033032990     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00449.x     Document Type: Article

References (31)

1. Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor LY307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110: A161(Abstract).
2. Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
3. Dammann HG, Burkhardt F, Bell NE, Bjaaland T. Rabeprazole effectively inhibits 24-hour H+ activity and nocturnal acid secretion in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
4. Cloud ML, Enas N, Humphries TJ, Bassion S and the US Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
5. Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug-drug interaction evaluation of rabeprazole sodium: a clean/expected slate? Gut 1996; 39(Suppl. 3): A47(Abstract).
6. Graham FY, McCollough A, Sklar M, et al. Omeprazole versus placebo in duodenal ulcer healing - the United States experience. Dig Dis Sci 1990; 35: 66-72.
7. Mulder CJJ, Schipper DL. Omeprazole and ranitidine in duodenal ulcer healing - analysis of comparative clinical trials. Scand J Gastroenterol 1990; 25(Suppl. 178): 62-6.
8. Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Stat Med 1984; 3: 199-214.
9. Casagrande JT, Pike MC, Smith PG. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978; 34(3): 483-6.
10. Jones DB, Howden CW, Burgett DW, Smith PG. Acid suppression in duodenal ulcer: a meta-analysis to define optimum dosing with antisecretory drugs. Gut 1987; 28: 1120-7.
11. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
12. Holt S. Proton-pump inhibition for acid-related disease. South Med J 1991; 84: 1078-87.
13. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
14. Chleram P, Goh KL, Leong YP, et al. Omeprazole compared with ranitidine in the treatment of duodenal ulcer. J Gastroenterol Hepatol 1989; 2: 53-61.
15. McFarland RJ, Bateson MC, Green JRB, et al. Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 1990; 98: 278-83.
16. Hui WM, Lam SK, Lau WY, et al. Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomised double-blind study with weekly endoscopic assessment. J Gastroenterol Hepatol 1989; 4 (Suppl. 2): 35-43.
17. Marks IN, Winter TA, Lucke W, et al. Omeprazole and ranitidine in duodenal ulcer healing. S Afr Med J 1988; 74: 54-6.
18. Classen M, Dammann HG, Domschke W, et al. Omeprazole versus ranitidine in the treatment of duodenal ulcer: a German multicentre trial. Deutsch Med Wochenchr 1985; 110: 210-15.
19. Mulder CJJ, Tytgat GNJ, Cluysenaer OJJ, et al. Omeprazole (20 mg o.m.) versus ranitidine (150 mg b.d.) in duodenal ulcer healing and pain relief. Aliment Pharmacol Ther 1989; 3: 445-51.
20. Barbara L, Blasi A, Cheli R, et al. Omeprazole versus ranitidine in the short-term treatment of duodenal ulcer: an Italian multicentre study. Hepatogastoenterology 1987; 34: 299-32.
21. Bardhan KD, Bianchi Porro G, Bose K, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 1986; 8: 408-13.
22. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 36: 22438-46.
23. Williams MP, Sercombe J, Pounder RE. A placebo-controlled trial to assess the effects of eight days of dosing with rabeprazole versus omeprazole on the 24-hour gastric acidity and plasma gastrin concentrations in young healthy subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
24. Carlsson E, Larsson H, Mattsson H, Pyberg B, Sundell G. Pharmacology and toxicology of omeprazole - with special reference to the effects on the gastric mucosa. Scand J Gastroenterol 1986; 118: 31-8.
25. Festen HPM, Tuynman HA, Defize J, et al. Effects of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting gastrin and serum pepsinogen I levels. Dig Dis Sci 1986; 31: 561-6.
26. Walsh JH, Sytnik B, Maxwell V, et al. Reversibility of plasma gastrin changes induced by omeprazole or ranitidine in man. Am J Gastroenterol 1988; 83: A1042(Abstract).
27. Lamberts R, Creutzfeldt W, Stockmann F, Jacubascke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988; 38: 126-35.
28. Maton PN. Omeprazole. N Engl J Med 1991; 324: 965-75.
29. Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - A European multicentre study. Aliment Pharmacol Ther 1998; 12: 789-95.
30. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
31. Howden CW. Clinical expressions of Helicobacter pylori infection. Am J Med 1996; 100: S27-34.